https://www.pharmaradar360.com/article/regulation-of-ai-in-healthcare-10f88174ca8f7445Pharma Surgeen2026-06-11T11:00:01.000ZRegulation of AI in Healthcarehttps://www.pharmaradar360.com/article/relmada-therapeutics-appoints-cns-drug-development-veteran-michael-quirk-as-seni-205d264caf7d86c9Pharma Surgeen2026-06-11T11:00:00.000ZRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Programhttps://www.pharmaradar360.com/article/research-national-commission-into-the-regulation-of-ai-in-healthcare-research-en-21bb1db32095ead8Pharma Surgeen2026-06-11T11:00:00.000ZResearch: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findingshttps://www.pharmaradar360.com/article/merck-animal-health-to-acquire-targan-2f6b4330db3ef43bPharma Surgeen2026-06-11T10:45:58.000ZMerck Animal Health to Acquire TARGANhttps://www.pharmaradar360.com/article/l-industrie-pharmaceutique-appelle-le-g7-a-investir-dans-l-innovation-pour-stimu-eae612766dc14463Pharma Surgeen2026-06-11T09:35:08.000ZL'industrie pharmaceutique appelle le G7 à investir dans l'innovation pour stimuler la compétitivité, la résilience et la croissancehttps://www.pharmaradar360.com/article/imuldosa-c-s-sol-in-130mg-26ml-5mg-ml-d387045970c061acPharma Surgeen2026-06-11T08:58:50.000ZΑνάκληση παρτίδων του φαρμακευτικού προϊόντος IMULDOSA C/S.SOL.IN 130MG/26ML (5MG/ML)https://www.pharmaradar360.com/article/medical-devices-ask-for-a-regulatory-advice-meeting-from-the-mhra-7c78aa5bda84204bPharma Surgeen2026-06-11T07:48:47.000ZMedical devices: ask for a regulatory advice meeting from the MHRAhttps://www.pharmaradar360.com/article/pharmaceutical-industry-calls-on-g7-to-invest-in-innovation-to-drive-competitive-5108affff37cb403Pharma Surgeen2026-06-11T06:55:15.000ZPharmaceutical industry calls on G7 to invest in innovation to drive competitiveness, resilience, and growthhttps://www.pharmaradar360.com/article/fda-grants-priority-review-for-roche-s-tecentriq-for-a-certain-type-of-stage-iii-93694650d74349fdPharma Surgeen2026-06-11T05:00:00.000ZFDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancerhttps://www.pharmaradar360.com/article/shinsa-list-of-approved-medical-devices-april-2004-to-september-2025-ac2f2ddaaf2000e9Pharma Surgeen2026-06-11T03:00:00.000Z[SHINSA]List of Approved Medical Devices: April 2004 to September 2025https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-de63185ae8e7b009Pharma Surgeen2026-06-11T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-e93e0c3ff4089d73Pharma Surgeen2026-06-11T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-72fa36a0a4a4afb1Pharma Surgeen2026-06-11T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-e87ba35131f768b1Pharma Surgeen2026-06-11T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-04194922ceae2a3dPharma Surgeen2026-06-11T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-bee89148916908c6Pharma Surgeen2026-06-11T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-62f2f63c1b45fd06Pharma Surgeen2026-06-11T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-35298bc8ae37887fPharma Surgeen2026-06-11T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-d43ab4aaec3bc297Pharma Surgeen2026-06-11T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-4f343a4daa310fd2Pharma Surgeen2026-06-11T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-f2a24dfe04e8d07ePharma Surgeen2026-06-11T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-7c1bd4e5f3dc3bffPharma Surgeen2026-06-11T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-30345c83e11ff162Pharma Surgeen2026-06-11T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-eaaf54f94598bec1Pharma Surgeen2026-06-11T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/acrp-fellow-encourages-flexibility-creativity-and-persistence-in-clinical-resear-d8c21a61db1638e9Pharma Surgeen2026-06-10T21:26:50.000ZACRP Fellow Encourages Flexibility, Creativity, and Persistence in Clinical Researchhttps://www.pharmaradar360.com/article/anmat-consolido-su-participacion-en-los-principales-espacios-internacionales-de-a6014d1a9ea04878Pharma Surgeen2026-06-10T18:26:07.000ZANMAT consolidó su participación en los principales espacios internacionales de regulación farmacéuticahttps://www.pharmaradar360.com/article/three-deals-in-six-days-everest-builds-late-stage-apac-portfolio-b6144bc862643edfPharma Surgeen2026-06-10T16:00:00.000ZThree deals in six days: Everest builds late-stage APAC portfoliohttps://www.pharmaradar360.com/article/3-fragen-an-unser-neues-boardmitglied-lauren-mcnamer-general-manager-von-lilly-s-dd58111caa29b7eaPharma Surgeen2026-06-10T15:17:39.000Z3 Fragen an unser neues Boardmitglied: Lauren McNamer, General Manager von Lilly Switzerlandhttps://www.pharmaradar360.com/article/zepbound-tirzepatide-and-shaquille-o-neal-launch-national-campaign-after-nba-leg-493743c6f37b4aacPharma Surgeen2026-06-10T13:30:00.000ZZepbound® (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatablehttps://www.pharmaradar360.com/article/celebrating-our-aspen-aspire-leadership-graduates-97af457c2334448aPharma Surgeen2026-06-10T13:20:53.000ZCelebrating our Aspen Aspire Leadership Graduateshttps://www.pharmaradar360.com/article/antengene-s-atg-201-gains-ind-clearance-in-china-a351e0b64f6dcca3Pharma Surgeen2026-06-10T13:00:00.000ZAntengene’s ATG-201 gains IND clearance in Chinahttps://www.pharmaradar360.com/article/allergan-aesthetics-releases-the-aesthetics-evolution-what-consumers-really-want-5a87b0ed5b11656cPharma Surgeen2026-06-10T12:00:00.000ZAllergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aestheticshttps://www.pharmaradar360.com/article/opportunities-for-patients-and-the-public-to-be-involved-in-the-work-of-the-mhra-8495d3dc8baed1e0Pharma Surgeen2026-06-10T11:26:08.000ZOpportunities for patients and the public to be involved in the work of the MHRAhttps://www.pharmaradar360.com/article/company-sellas-life-sciences-df8a2c2b7cd408acPharma Surgeen2026-06-10T10:31:56.000ZCompany - Sellas Life Scienceshttps://www.pharmaradar360.com/article/ibento-ibento-workshop-on-new-approach-methodologies-nams-held-following-iccr-20-4329d3d1643c3425Pharma Surgeen2026-06-10T03:00:00.000Z[IBENTO][IBENTO]Workshop on New Approach Methodologies (NAMs) Held following ICCR-20​https://www.pharmaradar360.com/article/update-on-patient-enrollment-in-phase-2-study-of-enzomenib-for-acute-leukemia-325c6873bf0725d8Pharma Surgeen2026-06-10T02:30:00.000ZUpdate on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemiahttps://www.pharmaradar360.com/article/how-summer-heat-can-impact-migraines-35cc0dc7e26973e7Pharma Surgeen2026-06-10T00:00:00.000ZHow Summer Heat Can Impact Migraineshttps://www.pharmaradar360.com/article/fda-approves-lilly-s-ebglyss-lebrikizumab-lbkz-for-one-maintenance-dose-every-ei-9d4fc7426a3911aaPharma Surgeen2026-06-09T22:18:00.000ZFDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitishttps://www.pharmaradar360.com/article/u-s-fda-accepts-takeda-sbla-for-review-in-pediatric-uc-and-crohn-s-disease-4216f81039e6b730Pharma Surgeen2026-06-09T20:30:12.000ZU.S. FDA Accepts Takeda sBLA for Review in Pediatric UC and Crohn’s Diseasehttps://www.pharmaradar360.com/article/jean-francois-brochard-elu-president-du-leem-et-composition-du-nouveau-bureau-801859f77000f7d7Pharma Surgeen2026-06-09T16:22:37.000ZJean-François Brochard élu Président du Leem et composition du nouveau Bureauhttps://www.pharmaradar360.com/article/acceso-pre-registro-asistencia-telematica-c80d4e46b0cbb943Pharma Surgeen2026-06-09T16:13:43.000ZAcceso Pre-registro Asistencia Telemáticahttps://www.pharmaradar360.com/article/innovent-submits-nda-for-cldn18-2-adc-for-gastric-cancer-daa68cf3c1501774Pharma Surgeen2026-06-09T16:00:00.000ZInnovent submits NDA for CLDN18.2 ADC for gastric cancerhttps://www.pharmaradar360.com/article/nmpa-gives-conditional-nods-to-drugs-by-lupeng-vcare-staidson-c88f64ff9fcc09b5Pharma Surgeen2026-06-09T16:00:00.000ZNMPA gives conditional nods to drugs by Lupeng, Vcare, Staidsonhttps://www.pharmaradar360.com/article/gsk-enters-agreement-to-acquire-nuvalent-inc-7d7b7e5faa37410fPharma Surgeen2026-06-09T12:00:00.000ZGSK enters agreement to acquire Nuvalent, Inc.https://www.pharmaradar360.com/article/promotional-material-national-ai-commission-ask-me-anything-bfe3aa0539014dd3Pharma Surgeen2026-06-09T11:31:32.000ZPromotional material: National AI Commission: Ask Me Anythinghttps://www.pharmaradar360.com/article/guidance-ai-airlock-simulation-workshops-62f59d59ddb2fd1bPharma Surgeen2026-06-09T10:41:05.000ZGuidance: AI Airlock Simulation Workshopshttps://www.pharmaradar360.com/article/guidance-ai-airlock-sandbox-phase-2-programme-report-e042e8b71b7377dePharma Surgeen2026-06-09T10:37:42.000ZGuidance: AI Airlock Sandbox Phase 2 Programme Reporthttps://www.pharmaradar360.com/article/31-6204144f8c50e3b7Pharma Surgeen2026-06-09T10:08:24.000ZΛΙΣΤΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΔΙΑΘΕΣΙΜΟΤΗΤΑΣ 31 ΜΑΪΟΥhttps://www.pharmaradar360.com/article/emrn-884157d5592502edPharma Surgeen2026-06-09T09:59:21.000Zο ΕΟΦ είναι μέλος του Ευρωπαϊκού Δικτύου Ρυθμιστικών Αρχών Φαρμάκων (EMRN)https://www.pharmaradar360.com/article/the-guidance-on-digital-and-decentralised-clinical-trials-dct-has-been-updated-cfc2b16fbc16b9d6Pharma Surgeen2026-06-09T07:46:00.000ZThe guidance on digital and decentralised clinical trials (DCT) has been updatedhttps://www.pharmaradar360.com/article/ra-committee-townhall-how-agentic-ai-is-redefining-regulatory-excellence-58e5f910a0ab273aPharma Surgeen2026-06-09T07:39:41.000ZRA Committee Townhall – How Agentic AI is Redefining Regulatory Excellencehttps://www.pharmaradar360.com/article/un-multi-stakeholder-hearing-on-pandemic-prevention-preparedness-and-response-pp-cb41d961f6a7a91cPharma Surgeen2026-06-09T06:00:08.000ZUN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR)https://www.pharmaradar360.com/article/pharmac-to-fund-medicines-used-by-ambulance-providers-bfcb61eac3282003Pharma Surgeen2026-06-09T02:00:00.000ZPharmac to fund medicines used by ambulance providershttps://www.pharmaradar360.com/article/why-sleep-is-important-for-brain-health-74cb2281ea89d3b9Pharma Surgeen2026-06-09T00:00:00.000ZWhy Sleep Is Important for Brain Healthhttps://www.pharmaradar360.com/article/bausch-health-canada-inc-et-l-alliance-pancanadienne-pharmaceutique-concluent-av-f2f7997dc3e086bfPharma Surgeen2026-06-09T00:00:00.000ZBausch Health, Canada Inc. et l’Alliance pancanadienne pharmaceutique concluent avec succès leurs négociations, menant à la signature d’une lettre d’intention pour OKEDI MC (suspension injectable à libération prolongée de rispéridone) dans le traitement de la schizophréniehttps://www.pharmaradar360.com/article/bausch-health-canada-inc-and-the-pan-canadian-pharmaceutical-alliance-sign-lette-9e77384c46509b25Pharma Surgeen2026-06-09T00:00:00.000ZBausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of Pr OKEDI ® (Risperidone for extended-release injectable suspension) for the treatment of schizophreniahttps://www.pharmaradar360.com/article/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-eval-49971b9dd9fe51c3Pharma Surgeen2026-06-08T20:39:58.000ZGilead and Merck Announce Positive Topline Results from two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatmenthttps://www.pharmaradar360.com/article/merck-and-gilead-provide-update-on-phase-3-keynote-d46-evoke-03-study-2d8fc949202d0f77Pharma Surgeen2026-06-08T20:30:00.000ZMerck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Studyhttps://www.pharmaradar360.com/article/lilly-s-oral-glp-1-foundayo-orforglipron-delivered-superior-a1c-control-and-weig-8f0559512800821aPharma Surgeen2026-06-08T18:30:00.000ZLilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trialshttps://www.pharmaradar360.com/article/pharmaceutical-industry-s-response-to-the-ebola-bundibugyo-virus-disease-outbrea-e947f2438a0dac0bPharma Surgeen2026-06-08T14:50:02.000ZPharmaceutical industry’s response to the Ebola Bundibugyo virus disease outbreakhttps://www.pharmaradar360.com/article/crise-au-moyen-orient-un-impact-sur-les-prix-de-production-des-medicaments-a59e9e084e383264Pharma Surgeen2026-06-08T14:42:29.000ZCrise au Moyen-Orient, un impact sur les prix de production des médicamentshttps://www.pharmaradar360.com/article/u-s-court-of-appeals-for-the-federal-circuit-affirms-victory-for-cormedix-therap-d7ddbf65e48c850bPharma Surgeen2026-06-08T14:41:08.000ZU.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT AFFIRMS VICTORY FOR CORMEDIX THERAPEUTICS IN MINOCIN® PATENT LITIGATIONhttps://www.pharmaradar360.com/article/public-alert-no-030-2026-alert-on-the-withdrawal-of-levamisole-containing-medici-0424acf12a52a25dPharma Surgeen2026-06-08T14:21:01.000ZPublic Alert No. 030/2026: Alert on the Withdrawal of Levamisole-Containing Medicines as endorsed by the Italian Medicines Agency (AIFA) over serious Neurological riskshttps://www.pharmaradar360.com/article/public-alert-no-029-2026-recall-of-impala-brand-gel-nail-polish-products-by-braz-a28afeb5d5f02df1Pharma Surgeen2026-06-08T14:15:56.000ZPublic Alert No. 029/2026 – Recall of Impala Brand Gel Nail Polish Products by Brazilian Health Regulatory Authority(ANVISA)https://www.pharmaradar360.com/article/public-alert-no-028-2026-recall-of-children-s-ibuprofen-oral-suspension-in-the-u-d64e33c10720829bPharma Surgeen2026-06-08T14:10:00.000ZPublic Alert No. 028/2026- Recall Of Children’s Ibuprofen Oral Suspension in the United States Due To Potential Contamination With Foreign Materialhttps://www.pharmaradar360.com/article/corporate-report-advertising-investigations-may-2026-300c34f00549b3cePharma Surgeen2026-06-08T13:37:42.000ZCorporate report: Advertising investigations: May 2026https://www.pharmaradar360.com/article/geef-uw-mening-over-een-genetisch-gewijzigd-geneesmiddel-tegen-retinoschisis-0e14ea604e0c43f1Pharma Surgeen2026-06-08T13:22:38.000ZGeef uw mening over een genetisch gewijzigd geneesmiddel tegen retinoschisishttps://www.pharmaradar360.com/article/pharmaceutical-industry-s-response-to-the-ebola-bundibugyo-virus-disease-outbrea-0f83a94241cc5663Pharma Surgeen2026-06-08T13:08:16.000ZPharmaceutical industry’s response to the Ebola Bundibugyo virus disease outbreakhttps://www.pharmaradar360.com/article/china-s-nmpa-clears-hansoh-s-hs-10541-for-clinic-b06cc76eb8a1d6faPharma Surgeen2026-06-08T13:00:00.000ZChina’s NMPA clears Hansoh’s HS-10541 for clinichttps://www.pharmaradar360.com/article/nafdac-joins-federal-ministry-of-health-social-welfare-national-food-safety-mana-75df1fe0b1af974aPharma Surgeen2026-06-08T12:59:29.000ZNAFDAC Joins Federal Ministry of Health & Social Welfare, National Food Safety Management Committee and the rest of the world in celebrating World Food Safety Dayhttps://www.pharmaradar360.com/article/exozymes-inc-announces-pricing-of-public-offering-of-common-stock-and-warrants-720962b226af3accPharma Surgeen2026-06-08T12:59:08.000ZeXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants